Unknown

Dataset Information

0

The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.


ABSTRACT: BACKGROUND:The T2-FLAIR mismatch sign is an imaging finding highly suggestive of isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted (non-codel) gliomas (astrocytomas). In previous studies, it has shown excellent specificity but limited sensitivity for IDH-mut astrocytomas. Whether the mismatch sign is a marker of a clinically relevant subtype of IDH-mut astrocytomas is unknown. METHODS:We included histopathologically verified supratentorial lower-grade gliomas (LGG) WHO grade II-III retrospectively during the period 2010-2016. In the period 2017-2018, patients with suspected LGG radiologically were prospectively included, and in this cohort other diagnoses than glioma could occur. Clinical, radiological and molecular data were collected. For clinical evaluation we included all patients with IDH-mut astrocytomas. In the 2010-2016 cohort DNA methylation analysis with Infinium MethylationEPIC BeadChip (Illumina) was performed for patients with an IDH-mut astrocytoma with available tissue. We aimed to examine the association of the T2-FLAIR mismatch sign with clinical factors and outcomes. Additionally, we evaluated the diagnostic reliability of the mismatch sign and its relation to methylation profiles. RESULTS:Out of 215 patients with LGG, 135 had known IDH-mutation and 1p19q codeletion status. Fifty patients had an IDH-mut astrocytoma and 12 of these (24.0%) showed a mismatch sign. The sensitivity and specificity of the mismatch sign for IDH-mut detection were 26.4 and 97.6%, respectively. There were no differences between patients with an IDH-mut astrocytoma with or without mismatch sign when grouped according to T2-FLAIR mismatch sign with respect to baseline characteristics, clinical outcomes and methylation profiles. The overall interrater agreement between neuroradiologist and clinical neurosurgeons for the T2-FLAIR mismatch sign was significant when all 215 MRI examination assessed (??=?0.77, p?

SUBMITTER: Corell A 

PROVIDER: S-EPMC7238512 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6120363 | BioStudies
2019-01-01 | S-EPMC6924170 | BioStudies
2020-01-01 | S-EPMC7212872 | BioStudies
2019-01-01 | S-EPMC7028667 | BioStudies
2017-01-01 | S-EPMC5432658 | BioStudies
2021-01-01 | S-EPMC7785563 | BioStudies
1000-01-01 | S-EPMC5373859 | BioStudies
2017-01-01 | S-EPMC5737620 | BioStudies
2020-01-01 | S-EPMC7058442 | BioStudies
1000-01-01 | S-EPMC5761503 | BioStudies